Esta traducción se está preparando. Mientras tanto, mostramos temporalmente la versión original en inglés.
Regulación y derecho · 29/11/20171 min de lectura
Prospective Grant of Exclusive Patent Commercialization License: N6, A Novel, Broad, Highly Potent HIV-Specific Antibody
Traducción automática local · Idioma original de la fuente
Resumen
The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent commercialization license to GlaxoSmithKline Intellectual Property Development Ltd (GSK) located at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.
Idioma original de la fuente: Federal Register — All DocumentsAbrir el comunicado original →